| 0.353 -0.007 (-1.92%) | 07-01 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 0.48 | 1-year : | 0.58 |
| Resists | First : | 0.41 | Second : | 0.5 |
| Pivot price | 0.35  |
|||
| Supports | First : | 0.27 | Second : | 0.22 |
| MAs | MA(5) : | 0.33 |
MA(20) : | 0.36 |
| MA(100) : | 0.64 |
MA(250) : | 0.97 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 47.9 |
D(3) : | 30.3 |
| RSI | RSI(14): 40.1 |
|||
| 52-week | High : | 2.38 | Low : | 0.27 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ HOWL ] has closed above bottom band by 44.6%. Bollinger Bands are 62.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 9 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.37 - 0.37 | 0.37 - 0.37 |
| Low: | 0.34 - 0.34 | 0.34 - 0.34 |
| Close: | 0.35 - 0.35 | 0.35 - 0.36 |
Werewolf Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing novel therapies that activate the body's immune system to combat cancer. Leveraging its exclusive PREDATOR platform, the company crafts conditionally activated molecules designed to stimulate both adaptive and innate immunity. This strategic approach aims to circumvent the shortcomings often associated with traditional proinflammatory immune treatments. Key among its product pipeline are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule targeting advanced solid tumors, and WTX-330, an Interleukin-12 INDUKINE molecule also designed for conditional activation, intended for advanced or metastatic solid tumors or lymphomas that have relapsed or are refractory. Furthermore, Werewolf Therapeutics is progressing WTX-613, a conditionally activated interferon alpha INDUKINE molecule, for addressing solid tumors and hematologic malignancies. The company was founded in 2017 and operates from its headquarters in Cambridge, Massachusetts.
Wed, 01 Jul 2026
Werewolf Therapeutics, Inc. Financial Disclosures & SEC Filings - TradingView
Mon, 29 Jun 2026
Werewolf Therapeutics director Luke Evnin sells $47,125 in stock By Investing.com - Investing.com South Africa
Mon, 29 Jun 2026
Entities tied to Werewolf Therapeutics (HOWL) director Luke Evnin sell 157K shares - Stock Titan
Mon, 29 Jun 2026
[144] Werewolf Therapeutics, Inc. SEC Filing - Stock Titan
Sat, 27 Jun 2026
Werewolf Therapeutics, Inc. Actuals & Estimates (NASDAQ:HOWL) - TradingView
Fri, 26 Jun 2026
RA Capital reports 6% Werewolf Therapeutics (HOWL) stake after June share sales - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 49 (M) |
| Shares Float | 44 (M) |
| Held by Insiders | 5.6 (%) |
| Held by Institutions | 30.1 (%) |
| Shares Short | 965 (K) |
| Shares Short P.Month | 668 (K) |
| EPS | -1.22 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.25 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -39.1 % |
| Return on Equity (ttm) | -161.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.7 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.03 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -52 (M) |
| Levered Free Cash Flow | -31 (M) |
| PE Ratio | -0.3 |
| PEG Ratio | 0 |
| Price to Book value | 1.41 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.34 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|